Abstract The coronavirus disease 2019 (COVID-19) pandemic is one of the most
consequential global health crises in over a century. Since its discovery in 2019, severe …

Die SARS-CoV-2-Pandemie stellte unser gesamtes Gesundheitssystem vor große
Herausforderungen. Beispiellos im Zuge der Pandemie wird Evidenz in Studien generiert …

The coronavirus disease 2019 (COVID-19) pandemic has reached a turning point. The non-
pharmaceutical interventions for preventing COVID-19 are lifting. Vaccination uptake is …

Objective To compare the effectiveness of Paxlovid vs. sotrovimab and molnupiravir in
preventing severe COVID-19 outcomes in non-hospitalised high-risk COVID-19 adult …

Background In this study, we aimed to compare the effectiveness and adverse reactions of
nirmatrelvir/ritonavir and molnupiravir in high-risk outpatients with coronavirus disease 2019 …

INTRODUCTION—At the end of 2019, a novel coronavirus rapidly spread throughout the
world, resulting in a global pandemic. The virus was designated severe acute respiratory …

Abstract Nirmatrelvir/ritonavir (N/R) is one of the most effective antiviral drugs against SARS-
CoV-2. The preclinical development, pharmacodynamics and pharmacokinetics of N/R are …

Introduction Molnupiravir and nirmatrelvir/ritonavir are antivirals used to prevent progression
to severe SARS-CoV-2 infections and decrease hospitalisation and mortality rates …

This study aimed to assess pulmonary changes at 6-month follow-up CT and predictors of
pulmonary residual abnormalities and fibrotic-like changes in COVID-19 pneumonia …

Background: Clinicians and patients want to know the benefits and harms of outpatient
treatment options for the Omicron variant of SARS-CoV-2. Purpose: To assess the benefits …